APOB and atherosclerosis: While anacetrapib was already proven effective in reducing ASCVD in REVEAL, obicetrapib has been shown to achieve twice the LDL-C and apoB reduction compared to anacetrapib, and thus potentially a greater reduction in ASCVD risk.